VANCOUVER, British Columbia, Nov. 17, 2026 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that it has agreed to grant stock options (the “Options”) to purchase 300,000 common shares in the capital of the Company (each, a “Common Share”) to a member of its Scientific Advisory Board.

The Options are exercisable at a price of c$0.25 per Common Share, will have a term of ten (10) years, and will vest quarterly over 24 months from the date of grant. The Options were granted pursuant to the Company’s amended and restated long-term incentive plan dated August 27, 2026, as amended on November 5, 2026 (the “Plan”). The Options are subject to the terms and conditions prescribed by the Plan, the Canadian Securities Exchange (the “CSE”), and applicable securities laws.

Globenewswire